文献速递妇科

统一的分子分型:单次检测ProMisE NGS工具的评估

Harmonized molecular classification; assessment of a single-test ProMisE NGS tool.
PubMed 文献 · Gynecol Oncol · 2023-06-14

研究评估单次DNA靶向NGS分子分型工具(ProMisE NGS)与原始ProMisE分型的一致性及预后价值,164例子宫内膜癌中159例一致(kappa=0.96,总体准确率0.97),新分型再现原分型的生存曲线,匹配活检与子宫切除样本一致率100%。

要点

  • ProMisE NGS在164例子宫内膜癌中与原始ProMisE分型一致159例,kappa=0.96,总体准确率0.97。
  • 新NGS分型再现原始ProMisE四亚型间无进展生存、疾病特异性生存和总生存的预后差异。
  • 匹配活检与子宫切除样本间ProMisE NGS一致率为100%。

核心结论

  • ProMisE NGS在标准FFPE材料上可行,与原始ProMisE分型高度一致并维持子宫内膜癌的预后价值。
  • 该检测有潜力促进在首次诊断时实施子宫内膜癌分子分型。

研究设计与样本

  • 从既往已行ProMisE分子分型(POLE测序、p53和MMR免疫组化)的FFPE子宫内膜癌组织中提取DNA。
  • 使用经临床验证的Imagia Canexia Health Find It™扩增子NGS基因面板检测致病性POLE突变、TP53突变(替代p53免疫组化)和微卫星不稳定性(MSI,替代MMR免疫组化),按原始ProMisE相同分离顺序进行亚型判定。
  • 共164例子宫内膜癌,比较两种分型工具的一致性指标和Kaplan-Meier生存统计。

主要发现

  • 164例中159例与原始ProMisE分型一致,kappa统计量为0.96,总体准确率为0.97。
  • 新NGS分型观察到四种分子亚型间无进展生存、疾病特异性生存和总生存的预后差异,再现原始ProMisE分型的生存曲线。
  • 匹配活检与子宫切除样本间ProMisE NGS一致率为100%。

临床怎么用

  • 原文结论指出ProMisE NGS在标准FFPE材料上可行,与原始ProMisE分型高度一致并维持预后价值。
  • 原文结论指出该检测有潜力促进在首次诊断时实施子宫内膜癌分子分型。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Despite recommendations for integrating molecular classification of endometrial cancers (EC) into pathology reporting and clinical management, uptake is inconsistent. To assign ProMisE subtype, all molecular components must be available (POLE mutation status, mismatch repair (MMR) and p53 immunohistochemistry (IHC)) and often these are assessed at different stages of care and/or at different centres resulting in delays in treatment. We assessed a single-test DNA-based targeted next generation sequencing (NGS) molecular classifier (ProMisE NGS), comparing concordance and prognostic value to the original ProMisE classifier. METHODS: DNA was extracted from formalin-fixed paraffin embedded (FFPE) ECs that had previously undergone ProMisE molecular classification (POLE sequencing, IHC for p53 and MMR). DNA was sequenced using the clinically validated Imagia Canexia Health Find It™ amplicon-based NGS gene panel assay to assess for pathogenic POLE mutations (unchanged from original ProMisE), TP53 mutations (in lieu of p53 IHC), and microsatellite instability (MSI) (in lieu of MMR IHC),with the same order of segregation as original ProMisE used for subtype assignment. Molecular subtype assignment of both classifiers was compared by concordance metrics and Kaplan-Meier survival statistics. RESULTS: The new DNA-based NGS molecular classifier (ProMisE NGS) was used to determine the molecular subtype in 164 ECs previously classified with ProMisE. 159/164 cases were concordant with a kappa statistic of 0.96 and an overall accuracy of 0.97. Prognostic differences in progression-free, disease-specific and overall survival between the four molecular subtypes were observed for the new NGS classifier, recapitulating the survival curves of the original ProMisE classifier. ProMisE NGS was 100% concordant between matched biopsy and hysterectomy samples. CONCLUSION: ProMisE NGS is feasible on standard FFPE material, demonstrates high concordance with the original ProMisE classifier and maintains prognostic value in EC. This test has the potential to facilitate implementation of molecular classification of EC at the time of first diagnosis.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Jamieson A, McConechy MK, Lum A, et al. Harmonized molecular classification; assessment of a single-test ProMisE NGS tool. Gynecol Oncol. 2023. PMID: 37321155. doi:10.1016/j.ygyno.2023.05.073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。